New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 28, 2014
10:37 EDTNWBONorthwest Biotherapeutics slides after presentation at cancer conference
Northwest Biotherapeutics (NWBO), a development-stage company focused on immunotherapy products that generate and enhance immune system responses to treat cancer, is trading down sharply after the company presented information about its cancer vaccine DC-Vax. The company's disclosures about the brain cancer study had issues, according to a report by Adam Feuerstein of The Street. WHAT'S NOTABLE: Yesterday, Northwest Biotherapeutics disclosed information about its cancer vaccine DC-Vax and its ongoing phase III brain cancer study during a presentation at the New York Academy of Medicine. Feuerstein's report contended that the information was "amazingly negative" and that CEO Linda Powers "spun the bad news in the opposite direction." The biotech reporter added that Powers would not give specific details about patient enrollment in the study. PRICE ACTION: Northwest Biotherapeutics is trading down 62c, or 7.97%, to $7.16 in morning trading. Reference Link
News For NWBO From The Last 14 Days
Check below for free stories on NWBO the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 17, 2014
11:12 EDTNWBOOptions with decreasing implied volatility
Subscribe for More Information
July 16, 2014
08:20 EDTNWBONorthwest Biotherapeutics completes DCVax-Direct Phase 1 trial recruitment
Northwest Biotherapeutics announced that the Phase I portion of the company's Phase I/II DCVax-Direct clinical trial has completed its 36-patient target recruitment, and the company is now underway with preparations for the Phase II portion of this trial, as well as expansion of DCVax-Direct manufacturing. The Phase I/II trial is testing the safety and activity of DCVax-Direct in various types of cancer. The Phase I portion of the trial has involved testing of 3 different dose levels, and a diverse range of cancers. The patients enrolled in Phase I will continue to receive treatments in accordance with the protocol. With the closing of Phase I, the company is now preparing to initiate the Phase II portion of the trial. This second part of the Phase I/II study will target 24 or more patients in selected cancers. Additional trial sites are being brought on to facilitate and expedite enrollment. The company and its manufacturing partner, Cognate BioServices, are also expanding the manufacturing capacity for DCVax-Direct.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use